Hexose-6-phosphate dehydrogenase determines the reaction direction of 11β-hydroxysteroid dehydrogenase type 1 as an oxoreductase  by Atanasov, Atanas G et al.
FEBS 28620 FEBS Letters 571 (2004) 129–133Hexose-6-phosphate dehydrogenase determines the reaction direction
of 11b-hydroxysteroid dehydrogenase type 1 as an oxoreductaseAtanas G. Atanasov, Lyubomir G. Nashev, Roberto A.S. Schweizer,
Christoph Frick, Alex Odermatt*
Division of Nephrology and Hypertension, Department of Clinical Research, University of Berne, Freiburgstrasse 15, 3010 Berne, Switzerland
Received 2 June 2004; revised 24 June 2004; accepted 29 June 2004
Available online 6 July 2004
Edited by Judit OvadiAbstract The impact of hexose-6-phosphate dehydrogenase
(H6PDH) on 11b-hydroxysteroid dehydrogenase (11b-HSD)
type 1 activity was investigated upon coexpression in HEK-293
cells. Confocal microscopy analysis indicated colocalisation of
both enzymes at the lumenal side of the endoplasmic reticulum
(ER) membrane. Functional analysis in intact cells revealed
ﬁvefold stimulation of 11b-HSD1 oxoreductase activity and
sixfold decrease of dehydrogenase activity upon coexpression
with H6PDH, without changing kinetic parameters in cell
lysates. Thus, H6PDH directly determines the reaction direction
of 11b-HSD1 in intact cells as an oxoreductase without changing
intrinsic catalytic properties of 11b-HSD1 by regenerating
NADPH in the ER-lumen.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cortisone, an inactive prohormone, requires the oxoreduc-
tion of its 11-keto group into an 11-hydroxyl group to form
biologically active cortisol. The ratio of cortisone to cortisol is
controlled by 11b-hydroxysteroid dehydrogenase (11b-HSD)
enzymes (reviewed in [1]). 11b-HSD2 exclusively catalyses the
oxidation of cortisol to cortisone, thereby protecting the
mineralocorticoid receptor from cortisol and rendering speci-
ﬁcity for aldosterone in tissues such as kidney and colon. 11b-
HSD1 is a bidirectional enzyme, catalysing both oxidation and
oxoreduction with comparable eﬃciencies in cell lysates,
whereby oxoreduction is less stable and decreases upon prep-
aration of microsomes and puriﬁcation [2]. Experiments in
animals and humans indicated that 11b-HSD1, which is highly
expressed in liver and adipose tissue [1] and has been associ-
ated with obesity and type 2 diabetes mellitus [3], is predom-
inantly an oxoreductase in vivo [4–7].
Oxidation of glucocorticoids was also reported in cells de-
void of 11b-HSD2 including skin ﬁbroblasts [8], rat pituitary
GH3 cells [9], Leydig cells [10,11] and adipose stromal cells* Corresponding author. Fax: +41-31-632-9444.
E-mail address: alex.odermatt@dkf.unibe.ch (A. Odermatt).
Abbreviations: 11b-HSD, 11b-hydroxysteroid dehydrogenase; ER,
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doi:10.1016/j.febslet.2004.06.065[12]. Recent reports suggested that hexose-6-phosphate dehy-
drogenase (H6PDH), catalysing the ﬁrst two steps of pentose
phosphate pathway, may stimulate 11b-HSD1 oxoreduction
by generating NADPH in the ER-lumen. Patients with corti-
sone oxoreductase deﬁciency have mutations in both
HSD11B1, causing decreased expression of 11b-HSD1, and
H6PD, causing reduced H6PDH activity [13]. Furthermore, a
switch from 11b-HSD1 dehydrogenase to oxoreductase activ-
ity and an increase in H6PDH mRNA was observed during
diﬀerentiation of adipose stromal cells to mature adipocytes
[12]. However, the diﬀerentiation of adipose stromal cells into
adipocytes is a highly complex process with dramatic changes
in gene expression, making it diﬃcult to assess the relative
contribution of H6PDH on 11b-HSD1 function.
In line with a stimulatory eﬀect of H6PDH on 11b-HSD1,
Banhegyi et al. [14] demonstrated cooperativity between the two
enzymes in liver microsome experiments. However, dehydro-
genase activity was not measured and cortisone-dependent
stimulation of H6PDH activity was observed at 10–500 lM
cortisone, concentrations far from being physiological. Thus,
the use of liver microsomes to assess the physiological role of
H6PDH on 11b-HSD1 function is limited.
The present study aimed at the reconstitution of the eﬀects
of H6PDH on 11b-HSD1 activities in intact cells with no or
very low endogenous expression of these two enzymes.2. Materials and methods
2.1. Materials
Cell culturemedia and reagents for reverse transcription of RNAwere
from Invitrogen (Carlsbad, CA), [1,2,6,7-3H]-cortisol from Amersham
Bioscience (Piscataway, NJ), [1,2,6,7-3H]-cortisone from American
Radiolabelled Chemicals (St. Louis, MO), the SV total RNA isolation
system from Promega (Madison, WI) and reagents for TaqMan real-
time PCR from Applied Biosystems (Foster City, CA). Monoclonal
antibodies were from Roche Diagnostics (Rotkreuz, Switzerland) and
ﬂuorescent antibodies from Molecular Probes (Eugene, OR).
2.2. Construction of plasmids
The expression plasmid for C-terminally FLAG-tagged human 11b-
HSD1 was described previously [15]. Full length human hexose-6-
phosphate dehydrogenase cDNA was kindly provided by
Dr. P.J. Mason (Accession No. AJ012590 [16]). The H6PDH cDNA
was modiﬁed by introducing an EcoRI site and by changing the context
50 to the initiator ATG codon to a ‘‘Kozak’’ consensus sequence [17]
after PCR ampliﬁcation with the oligonucleotide 50-TGTGAATTCC-
GCCATGTGGAATATGCTCATAGTGGC-30. An XbaI site was
introduced immediately 30 of the stop codon with oligonucleotideblished by Elsevier B.V. All rights reserved.
130 A.G. Atanasov et al. / FEBS Letters 571 (2004) 129–13350-ATATCTAGATCATCCCAGGAAGGCGTCGTAG-30 or a C-
terminal c-myc-epitope (-EQKLISEEDL-COOH), separated from
the H6PDH sequence by a SGGS-linker, with oligonucleotide
50-ATATCTAGATCAGAGGTCTTCTTCTGAGATGAGTTTTTGT-
TCTGATCCTCCTGATCCCAGGAAGGCGTCGTAG-30. The PCR
product was sequenced and cloned into pcDNA3 expression vector
(Invitrogen) with EcoRI and XbaI.2.3. Cell culture and transient transfection
HEK-293 cells were cultured as described [18] and transfected at a
1:1 ratio with 11b-HSD1 and either H6PDH or control DNA
(pcDNA3 vector) using the Ca2þ-phosphate precipitation method.
Chinese hamster ovary (CHO) cells were grown in Ham’s-F12 medium
and transfected with FuGENE6 according to the manufacturer’s
manual (Roche). After 24 h, cells were incubated in steroid-free me-
dium for another 24 h, lysates prepared and activities determined. For
determination of enzyme activities in intact cells, 80 000 cells were
seeded per well on a 96-well plate at the time of the change to steroid-
free medium, followed by incubation for 24 h. 3T3-L1 mouse prea-
dipocytes were cultured and diﬀerentiated into adipocytes as described
[18].
2.4. RNA extraction, reverse transcription and quantitative PCR
Total RNA was extracted from HEK-293 cells using the SV total
RNA isolation system. Reverse transcription was performed in 20 ll
containing 2 lg total RNA, 100 U Superscript II reverse trans-
criptase, 1 lg Oligo(dT)12–18, 0.5 mM of each deoxynucleotide,
10 mM dithiothreitol, 40 U RnaseOUT recombinant ribonuclease
inhibitor and the manufacturer’s buﬀer (Invitrogen). Real-time
quantiﬁcation of H6PDH mRNA was analysed using an ABI7000
sequence detection system (Applied Biosystems) and TaqMan tech-
nology for highly accurate H6PDH mRNA quantitation. Reactions
were performed in 96-well plates in 25 ll of reaction buﬀer con-
taining TaqMan Universal PCR Master Mix and 100 ng cDNA.
Quantitative primer and probe sequences are available on request
(Assay-on-Demand). All reactions were multiplexed with 18S rRNA
control probe. Data were obtained as Ct values according to the
manufacturer’s guidelines.2.5. Immunoﬂuorescence analysis
Immunostaining was performed as described [15]. Brieﬂy, cells were
ﬁxed with 4% paraformaldehyde, washed, blocked in buﬀer containing
1% milk and incubated with 0.5% Triton X-100 for complete perme-
abilisation of membranes or 25 lM digitonin for selective permeabil-
isation of the plasma membrane. FLAG-tagged 11b-HSD1 was
detected using mouse anti-FLAG antibody M2 and ALEXA-488 goat
anti-mouse antibody. Myc-tagged H6PDH was detected with rabbit
anti-myc antibody and ALEXA-594 goat anti-rabbit antibody. Sam-
ples were analysed on an LSM410 confocal microscope (Carl Zeiss,
Goettingen, Germany).Fig. 1. Activity of 11b-HSD1 and expression of 11b-HSD1 and
H6PDH mRNA in 3T3-L1 preadipocytes and in fully diﬀerentiated
adipocytes. Cells were grown to conﬂuence as preadipocytes or were
diﬀerentiated into adipocytes by incubation with isobutylmethylxan-
thine, dexamethasone, and insulin for two days followed by incubation
in medium containing insulin for two more days and in absence of
insulin for another three days. (A) 11b-HSD1 activity was determined
as the percent conversion of cortisone to cortisol in intact cells incu-
bated for 3 h in medium containing [3H]cortisone. (B) 11b-HSD1
(white bars) and H6PDH mRNA levels (black bars) relative to 18S
control RNA were determined by quantitative real time TaqMan PCR.
Data were normalized to the ratio of 11b-HSD1 mRNA to 18S RNA
in preadipocytes. Data represent meansS.D. from three independent
experiments.2.6. 11b-HSD1 activity assay
For measurements in lysates, cells were washed, resuspended and
centrifuged for 3 min at 150· g. The supernatant was removed,
pellets were quick-frozen in a dry-ice ethanol bath and aliquots
stored at )70 C. 11b-HSD1 oxoreductase and dehydrogenase ac-
tivities in cell lysates were measured as described [18] in the presence
of 400 lM NADPH or NADP, respectively, with substrate con-
centrations ranging from 20 nM to 2.5 lM. Assays with intact cells
were carried out in 96-well plates. Cells were incubated in steroid-
free medium in the presence of various substrate concentrations in
the absence of exogenous cofactor for 1–3 h at 37 C. In all reac-
tions, the conversion of substrate to product was kept below 30%.
Steroids were separated by TLC and conversion analysed by scin-
tillation counting.
To semi-quantitatively assess Vmax, 30 lg of total proteins from
transfected cells was subjected to SDS–PAGE and Western blot
analysis using mouse anti-FLAG antibody M2 to detect FLAG-
tagged 11b-HSD1 and mouse anti-myc antibody to detect myc-
tagged H6PDH, followed by horseradish peroxidase-conjugated anti-
mouse IgG. Antibody binding was visualised using the enhanced
chemiluminescence (ECL) Western detection system (Pierce,
Rockford, IL).3. Results and discussion
3.1. Expression analysis of 11b-HSD1 and H6PDH in 3T3-L1
adipocytes
In line with previous observations [19,20], we reported re-
cently that 11b-HSD1 catalyses exclusively the oxoreduction
reaction in intact rat hepatocytes and fully diﬀerentiated
mouse 3T3-L1 adipocytes [18,21]. In contrast, transfected
HEK-293 cells equally well catalysed oxoreduction and oxi-
dation of glucocorticoids [15]. Here, we investigated the direct
eﬀect of H6PDH on 11b-HSD1 activities in intact cells.
First, we measured 11b-HSD1 activities and determined
mRNA levels of 11b-HSD1 and H6PDH in mouse 3T3-L1
preadipocytes and in fully diﬀerentiated adipocytes (Fig. 1).
While only background 11b-HSD1 activity was detectable in
3T3-L1 preadipocytes after incubation for 3 h (or even after
12 h, not shown), fully diﬀerentiated 3T3-L1 adipocytes eﬃ-
ciently catalysed the oxoreduction of cortisone (Fig. 1A), re-
sembling the activities in mature adipocytes. The increase in
11b-HSD1 activity upon diﬀerentiation to 3T3-L1 adipocytes
was reﬂected by a more than 100-fold increase in 11b-HSD1
mRNA in fully diﬀerentiated adipocytes (Fig. 1B). In contrast,
H6PDH mRNA only slightly increased during 3T3-L1 adi-
pocyte diﬀerentiation, reaching 2.5-fold higher levels seven
days after initiation of diﬀerentiation. This stands in contrast
to the diﬀerentiation of human adipose stromal cells to
adipocytes, where 11b-HSD1 mRNA did not change but
H6PDH mRNA increased twofold [13]. Thus, due to the lack
of substantial 11b-HSD1 expression, 3T3-L1 preadipocytes are
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stromal cells. The complex changes in protein expression
during adipocyte diﬀerentiation make it diﬃcult to dissect a
potential eﬀect of H6PDH on 11b-HSD1 activity from that of
other proteins. Therefore, we reconstituted the eﬀects of
H6PDH on 11b-HSD1 activities by expressing recombinant
enzymes in a cell system with no or very low endogenous levels.
3.2. Expression of recombinant 11b-HSD1 and H6PDH in
HEK-293 cells
PCR analysis revealed no endogenous 11b-HSD1 (not
shown) and only a very low level of H6PDH mRNA in HEK-
293 cells (Fig. 2A). Expression of recombinant H6PDH and
11b-HSD1 resulted in a more than 1000-fold increase in
mRNA level (Fig. 2A, not shown). As expected, the expression
of C-terminally myc-tagged H6PDH yielded a band at 90 kDa
[16]. Unspeciﬁc low molecular weight bands in control cells
and in H6PDH-transfected cells indicate that equal protein
amounts were separated by SDS–PAGE. Coexpression of both
proteins resulted in a decreased expression (37%) of 11b-HSD1
protein as determined by densitometry (Fig. 2B).Fig. 2. Expression of 11b-HSD1 and H6PDH in HEK-293 cells. Cells were t
total proteins separated by SDS–PAGE. (A) Detection of myc-tagged H6PD
PCR analysis. (B) Detection of FLAG-tagged 11b-HSD1 by Western blot an
software, NIH, USA) (data represent three independent experiments).
Fig. 3. Colocalisation of 11b-HSD1 and H6PDH to the ER-membrane. HEK
tagged H6PDH. After 48 h, cells were completely permeabilised with 0.5% T
anti-myc antibody and visualised using anti-mouse antibody ALEXA-488 and
microscopy. (A) Green ﬂuorescence representing 11b-HSD1; (B) red ﬂuoresc3.3. 11b-HSD1 and H6PDH colocalise at the lumenal side of
the ER-membrane
The intracellular distribution of FLAG-tagged 11b-HSD1
and myc-tagged H6PDH was analysed in transfected HEK-
293 cells after selectively permeabilising the plasma membrane
using 25 lM digitonin. No signal was detected for both en-
zymes; in contrast, using the same conditions, control cells
expressing FLAG-tagged 11b-HSD2 with cytoplasmic orien-
tation stained positive (not shown, [15]). These results conﬁrm
that 11b-HSD1 and H6PDH are ER-lumenal proteins. Dual
staining of completely permeabilised cells (0.5% Triton X-100)
and analysis by confocal microscopy revealed a nearly identi-
cal, typically reticular distribution pattern of 11b-HSD1 and
H6PDH (Fig. 3). An overlay image of the expression of
H6PDH and 11b-HSD1 indicated colocalisation of both pro-
teins at the ER-membrane. Although H6PDH was originally
puriﬁed from liver microsomal preparations [22] and was
found to be ﬁrmly bound to the ER-membrane upon washing
and trypsin digestion [23], H6PDH does not contain a mem-
brane spanning region nor was the protein known to which it is
associated. Clearly, further studies are required to assessransfected with the respective constructs, grown for 48 h and 30 lg of
H by Western blot and relative quantiﬁcation of mRNA by TaqMan
d relative quantiﬁcation of Western blot signals (performed by ImageJ
-293 cells were cotransfected with FLAG-tagged 11b-HSD1 and myc-
riton X-100, dual-labelled with mouse anti-FLAG antibody and rabbit
anti-rabbit antibody ALEXA-594. Samples were analysed by confocal
ence showing H6PDH; and (C) an overlay of (A) and (B).
Table 1
Eﬀect of H6PDH on 11b-HSD1-dependent interconversion of cortisone and cortisol
Transfection Oxoreduction of cortisone Oxidation of cortisol
Km (nM) Vmax
(nmol h1 mg1)
kcat (Vmax=Km)
(h1 mg1 · 103)
Km (nM) Vmax
(nmol h1 mg1)
kcat (Vmax=Km)
(h1 mg1 · 103)
(A) Intact cells
11b-HSD1 + pcDNA3 665 91 0.76 0.08 1.14 1093 185 1.74 0.3 1.59
11b-HSD1 + H6PDH 862 142 4.57 0.35 5.30 1103 272 0.26 0.07 0.24
11b-HSD1 + H6PDH-myc 807 128 4.21 0.21 5.22 1317 123 0.37 0.08 0.28
(B) Cell lysates
11b-HSD1 + pcDNA3 295 70 0.58 0.05 1.97 996  206 2.7  0.64 2.71
11b-HSD1 + H6PDH 254 88 0.44 0.06 1.73 1286 213 3.67 0.55 2.85
11b-HSD1 + H6PDH-myc 352 42 0.51 0.05 1.45 1203 243 3.2  0.6 2.66
HEK-293 cells were transfected with 11b-HSD1 and either wild-type H6PDH, C-terminally myc-tagged H6PDH or control DNA. After growth in
steroid-free medium for 24 h, activities were determined in intact cells (A) or lysates (B). Activities (means S.D.) were obtained from three
independent transfections, each measured in duplicate. Kinetic parameters were obtained by non-linear regression using Data Analysis Toolbox
(MDL Information System Inc.) assuming ﬁrst-order rate kinetics. For calculation of apparent Vmax, the amount of 11b-HSD1 protein was
compared by densitometric analysis of Western blots.
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direct physical interaction.
3.4. H6PDH determines the reaction direction of 11b-HSD1
In the absence of H6PDH, intact HEK-293 cells expressing
11b-HSD1 catalysed the oxoreduction of cortisone and the
oxidation of cortisol with a slight preference for the dehy-Fig. 4. H6PDH determines the reaction direction of 11b-HSD1. HEK-293 cel
line, A–D) or cotransfected with 11b-HSD1 and H6PDH (dashed line, A–D
resentative experiments measured in duplicate are shown. (B,D) Eadie–Hof
(solid line) or presence of H6PDH (dashed line). The intercept at the y-axis i
independent experiments measured in duplicate.drogenase reaction (Table 1, Fig. 4), making it a suitable sys-
tem to investigate the mechanisms aﬀecting reaction direction.
The ratio between oxoreductase and dehydrogenase activity
was comparable between intact cells (0.72) and cell lysates
(0.73) in the absence of H6PDH (Table 1). Coexpression with
H6PDH led to a ﬁvefold increase in oxoreductase activity and
a sixfold decrease in dehydrogenase activity without changingls were transfected with 11b-HSD1 and control pcDNA3 plasmid (solid
). (A,B) Oxoreduction of cortisone; (C,D) oxidation of cortisol. Rep-
stee plots demonstrate Michaelis–Menten kinetics both in the absence
ndicates Vmax (B,D). Data represent means S.D. obtained from three
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cantly altered Vmax without aﬀecting Km for both oxoreductase
and dehydrogenase activity, indicating that the availability of
the cofactor does not aﬀect the substrate aﬃnity of 11b-HSD1.
The ratio between oxoreductase and dehydrogenase activity
increased to 22 in intact cells but was not signiﬁcantly diﬀerent
in cell lysates (0.62) upon coexpression of H6PDH and 11b-
HSD1. The linearity of the data observed in Eadie-Hofstee
plots shows ﬁrst-order rate kinetics for 11b-HSD1 both in the
absence and presence of H6PDH (Fig. 4B and D).
Only background activities were detectable in cell lysates
when cofactor was omitted. In cell lysates, 11b-HSD1 exists in
an accessible form in open perinuclear and in multilamellar
membranes, whereas the enzyme seems to be inaccessible for
the cofactor and/or the substrate in tightly sealed ER-mem-
brane vesicles. Correspondingly, we observed approximately
twofold higher total enzymatic activities upon addition of
relatively mild detergents such as 0.5% C12E8, octylglucoside
or Nonidet P-40 (not shown). This is in line with Banhegyi et
al. [14] reporting cooperativity between 11b-HSD1 and
H6PDH in the ER-lumen and demonstrating that the activity
of both enzymes was latent in intact rat liver microsomal
vesicles.
Similar results were obtained with CHO cells. Coexpres-
sion with H6PDH did not aﬀect 11b-HSD1 activities in cell
lysates. In intact cells, coexpression with H6PDH stimulated
11b-HSD1-dependent oxoreduction of cortisone from kcat¼
1.8 0.2 h1 mg1 · 103 (Km¼ 662 81 nM, Vmax¼ 1.19
0.06 nmol h1 mg1) to kcat¼ 5.20 0.41 h1 mg1 103
(Km¼ 818 97 nM, Vmax¼ 4.28 0.29 nmol h1 ·mg1) and
completely abolished the oxidation reaction (from kcat¼ 0.60
0.05 h1 mg1 · 103, Km¼ 1172 159 nM, Vmax¼ 0.71 0.05
nmol h1 mg1).
In conclusion, these ﬁndings indicate that H6PDH coop-
erates with 11b-HSD1 by regenerating cofactor NADPH
without altering the intrinsic enzymatic properties of 11b-
HSD1. The analysis of the intracellular distribution of epi-
tope-tagged 11b-HSD1 and H6PDH constructs provides
evidence for colocalisation at the lumenal side of the ER-
membrane. The fact that activities in lysates in the absence
or presence of H6PDH were not signiﬁcantly diﬀerent sug-
gests a rather weak or short-lived interaction between 11b-
HSD1 and H6PDH. Importantly, the present ﬁndings dem-
onstrate for the ﬁrst time in intact cells that H6PDH not
only stimulates oxoreductase activity of 11b-HSD1 but also
determines the reaction direction by abolishing the dehy-
drogenase activity. These results strongly suggest that the
increasing expression of H6PDH during the diﬀerentiation
of adipocytes controls the observed switch from dehydro-
genase activity, favouring cell proliferation, to oxoreductase
activity, promoting adipocyte diﬀerentiation [12]. Like 11b-HSD1, H6PDH and the glucose-6-phosphate transporter in
the ER-membrane, supplying the substrate for H6PDH,
represent potential targets for therapeutic treatment of type
2 diabetes. Inhibitors of these enzymes should result in di-
minished local activation of glucocorticoids and are expected
to exert anti-diabetic eﬀects.
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